Form 8-K - Current report:
SEC Accession No. 0001193125-25-323798
Filing Date
2025-12-18
Accepted
2025-12-18 08:39:41
Documents
14
Period of Report
2025-12-18
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d84904d8k.htm   iXBRL 8-K 24448
2 EX-99.1 d84904dex991.htm EX-99.1 20610
6 GRAPHIC g84904g1218105026102.jpg GRAPHIC 6731
  Complete submission text file 0001193125-25-323798.txt   174435

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ovid-20251218.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20251218_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20251218_pre.xml EX-101.PRE 11258
16 EXTRACTED XBRL INSTANCE DOCUMENT d84904d8k_htm.xml XML 3632
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 251581396
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)